- Home
- TAK
as of 09-03-2026 3:46pm EST
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
| Founded: | 1781 | Country: | Japan |
| Employees: | N/A | City: | N/A |
| Market Cap: | 57.6B | IPO Year: | 2007 |
| Target Price: | N/A | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $12.99 - $18.89 | Next Earning Date: | 05-13-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 0.16% | Revenue Growth (next year): | 1.22% |
| P/E Ratio: | 41.25 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | +10.20% |
AI-Powered TAK Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) (TAK)
President, R&D
Avg Cost/Share
$18.49
Shares
116,191
Total Value
$2,148,371.59
Owned After
145,465
SEC Form 4
President, R&D
Avg Cost/Share
$18.49
Shares
19,651
Total Value
$363,346.99
Owned After
145,465
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$18.11
Shares
12,980
Total Value
$235,118.42
Owned After
40,049
SEC Form 4
Pres., Global Supply & Quality
Avg Cost/Share
$17.55
Shares
40,726
Total Value
$714,741.30
Owned After
67,311
President, OBU
Avg Cost/Share
$17.10
Shares
50,012
Total Value
$855,205.20
Owned After
252,010
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$17.10
Shares
14,006
Total Value
$239,502.60
Owned After
116,177
SEC Form 4
President, PDT BU
Avg Cost/Share
$17.10
Shares
7,277
Total Value
$124,436.70
Owned After
102,588
SEC Form 4
President, U.S. Business Unit
Avg Cost/Share
$17.10
Shares
16,901
Total Value
$289,007.10
Owned After
182,507
SEC Form 4
Chief Transformation Officer
Avg Cost/Share
$17.10
Shares
47,586
Total Value
$813,720.60
Owned After
226,057
SEC Form 4
President, R&D
Avg Cost/Share
$17.10
Shares
165,393
Total Value
$2,828,220.30
Owned After
145,465
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Plump Andrew Stewart | TAK | President, R&D | Sep 2, 2026 | Sell | $18.49 | 116,191 | $2,148,371.59 | 145,465 | |
| Plump Andrew Stewart | TAK | President, R&D | Aug 19, 2026 | Sell | $18.49 | 19,651 | $363,346.99 | 145,465 | |
| Greenway Nicola Deidre Petal | TAK | Chief Human Resources Officer | Aug 18, 2026 | Sell | $18.11 | 12,980 | $235,118.42 | 40,049 | |
| Shannon Elaine Mary | TAK | Pres., Global Supply & Quality | Aug 11, 2026 | Sell | $17.55 | 40,726 | $714,741.30 | 67,311 | |
| Bitetti Teresa Marie | TAK | President, OBU | Aug 10, 2026 | Sell | $17.10 | 50,012 | $855,205.20 | 252,010 | |
| Farajallah Awny Samaan Botros | TAK | Chief Medical Officer | Aug 10, 2026 | Sell | $17.10 | 14,006 | $239,502.60 | 116,177 | |
| Ibrahim Ramy Riad Ahmed | TAK | President, PDT BU | Aug 10, 2026 | Sell | $17.10 | 7,277 | $124,436.70 | 102,588 | |
| Pacheco Rhonda Janice | TAK | President, U.S. Business Unit | Aug 10, 2026 | Sell | $17.10 | 16,901 | $289,007.10 | 182,507 | |
| Duprey Lauren Rusckowski | TAK | Chief Transformation Officer | Aug 10, 2026 | Sell | $17.10 | 47,586 | $813,720.60 | 226,057 | |
| Plump Andrew Stewart | TAK | President, R&D | Aug 10, 2026 | Sell | $17.10 | 165,393 | $2,828,220.30 | 145,465 |
Compare TAK vs Leading Stocks
See how TAK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.